Scinai Immunotherapeutics SCNI Cash Flow Statement (2015-2026)

NASDAQ SCNI
$1.67 -0.04 (-2.34%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Scinai Immunotherapeutics Quarterly Cash Flow Statement

Periods 40 quarters
Latest Jun 2026

Scinai Immunotherapeutics reported cash from operations of -$2.46M and free cash flow of -$2.35M for the quarter ended Jun 2026, down 136.7% year over year. This cash flow statement covers 40 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2015 Jun2015 Dec2015 Mar2016 Dec2016 Mar2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-11.99M-9.05M37.43M-1.50M1.95M14.37M6.48M-3.52M10.79M-11.45M10.67M-2.16M6.64M10.46M-2.26M-1.57M-2.19M-2.47M-2.15M
Share-based CompensationStock Comp.
2.58M2.53M0.73M0.48M0.41M0.31M0.40M0.25M0.21M0.23M0.45M0.19M0.65M0.14M0.20M0.00M0.32M0.07M0.23M
Gains from Investment SecuritiesGains Investment
-2.57M-0.77M-0.59M-0.22M-0.10M0.00M
Non-cash ItemsNon-Cash Items
1.09M
Cash from OperationsCash from Ops.
-7.91M-6.19M-1.86M-1.10M-3.67M-1.90M-0.59M-3.06M-2.88M-2.22M-1.23M-1.46M-1.76M-2.04M-1.08M-1.04M-1.53M-1.46M-2.46M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.16M-0.02M0.00M0.00M0.06M0.07M0.11M0.06M0.04M0.07M-0.04M0.11M0.01M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.60M0.61M-1.35M0.13M0.14M0.10M0.18M0.14M0.15M0.14M0.08M0.16M0.50M0.50M0.50M0.35M0.35M0.45M0.59M
Change in Working Capital
Change in ReceivablesChange Receivables
-2.19M1.22M0.14M0.14M-0.13M-0.09M-0.21M0.15M-0.04M-0.00M0.12M0.05M-0.07M-0.02M-0.21M
Change in Account PayablesChange Payables
0.55M-0.61M0.77M0.31M-0.75M-0.14M0.89M0.63M-0.66M-0.10M-0.21M0.31M-0.18M-0.23M0.26M0.17M0.11M0.20M0.07M
Investing Activities
Capital ExpendituresCapex
-0.11M-0.00M-0.18M0.52M-0.04M-1.05M-0.27M-0.01M-0.38M-0.02M-0.23M-0.00M-0.01M-0.00M-0.01M-0.00M-0.00M-0.11M
Acquisitions
2.75M
Cash from Investing ActivitiesCash from Investing
-0.11M-0.01M-0.11M-0.52M0.04M-0.08M-0.27M-0.01M-0.38M-0.02M-0.23M-0.00M-0.01M-0.00M-0.01M-0.00M2.75M-0.11M
Financing Activities
Other financing activitiesOther financing
5.71M0.13M-0.00M-0.00M0.82M1.42M0.01M0.01M
Cash from Financing ActivitiesCash from Financing
-0.32M-0.99M8.88M1.42M0.01M0.01M2.00M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
28.89M28.92M97.55M413.20M
Net Equity Issued and RepurchasedNet Equity Issued
29.49M-0.68M-20.02M
Additional items
Exchange Rate EffectFX Effect
-0.36M1.98M-0.29M-0.36M-0.48M-0.99M-0.15M-0.22M-0.04M0.01M-0.01M-0.13M0.00M
Change in Cash
-8.69M-5.21M6.62M-1.99M-4.11M-2.97M5.76M-3.29M-3.29M-1.15M-1.47M-0.04M-1.87M-1.92M0.93M
Free Cash FlowFCF
-7.80M-6.18M-1.68M-1.63M-3.63M-0.85M-0.32M-3.05M-2.50M-2.20M-0.99M-1.46M-1.75M-2.03M-1.08M-1.03M-1.53M-1.45M-2.35M
Net Cash FlowNCF
-8.33M-7.19M6.91M-1.63M-3.63M-1.98M-0.86M-3.06M-3.25M-2.24M-1.46M-0.04M-1.75M-2.03M0.92M-1.05M-1.54M1.29M-2.58M